DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,170.00
-80.00 (-1.52%)
At close: Apr 28, 2026
-5.66%
Market Cap 139.81B
Revenue (ttm) 242.69B
Net Income (ttm) 50.27B
Shares Out 27.04M
EPS (ttm) 1,791.00
PE Ratio 2.89
Forward PE n/a
Dividend 120.00 (2.32%)
Ex-Dividend Date Dec 29, 2025
Volume 110,473
Average Volume 91,090
Open 5,220.00
Previous Close 5,250.00
Day's Range 5,150.00 - 5,250.00
52-Week Range 4,745.00 - 6,390.00
Beta 0.49
RSI 48.14
Earnings Date May 14, 2026

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip... [Read more]

Industry Pharmaceutical Preparations
Founded 1970
Employees 404
Stock Exchange KOSDAQ
Ticker Symbol 006620
Full Company Profile

Financial Performance

In 2025, DongKoo Bio & Pharma's revenue was 242.69 billion, a decrease of -2.64% compared to the previous year's 249.27 billion. Earnings were 50.27 billion, an increase of 2369.74%.

Financial Statements

News

There is no news available yet.